Clinical trials
Intermediate AMD clinical trials
Below are recruiting intermediate amd clinical trials, each written for real people, not researchers. We’re tracking 6 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06557369Recruiting
New light therapy for intermediate age-related macular degeneration
This trial tests a new light-based treatment for intermediate age-related macular degeneration (AMD), a common eye condition that can lead to vision loss. The goal is to see if it is safe and helps slow down the disease.
BergamoAges 50 years+ - NCT07189169RecruitingPhase 3
Testing QA108 for intermediate AMD
This trial tests an investigational medicine (QA108) for people with intermediate age-related macular degeneration (AMD). It aims to slow or prevent progression of the disease by treating the deposits (drusen) in the center of the retina.
BeijingAges 45–85 - NCT07515521Recruiting
Vision and Imaging Tests for Early and Intermediate AMD
This study tests new ways to measure vision and take detailed eye images in people with age-related macular degeneration (AMD), a common eye condition affecting central vision. The goal is to develop better tools for future AMD treatment trials.
BonnAges 18 years+ - NCT06662162Recruiting
Microcurrent therapy for dry age-related macular degeneration
This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.
Poway, CaliforniaAges 60 years+ - NCT07607496Recruiting
MacuTherm laser treatment study for intermediate age-related macular degeneration
This study tests a new laser treatment (MacuTherm) for intermediate age-related macular degeneration (iAMD), an eye condition that affects central vision. The study aims to see if this treatment can slow or prevent progression to more advanced stages of the disease.
DetmoldAges 60–90 - NCT04735263RecruitingTeam says not enrollingPhase 2
Testing dark vision changes as a statin response signal
This Phase 2 study looks at whether changes in night/dark adaptation can show early whether high-dose atorvastatin (a statin) is helping intermediate age-related macular degeneration (AMD). If you fit, you may help researchers find an earlier way to tell who is responding.
Boston, MassachusettsAges 50–85
Hear when a new Intermediate AMD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for intermediate amd?
- Yes. Clin2 currently lists 6 recruiting intermediate amd studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a intermediate amd trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a intermediate amd trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.